Blog
RSS FeedPosted by Michael Wonder on 11 Feb 2023
Digital health predictions: uncertainty will trigger innovation in 2023
7 February 2023 - It was an interesting year for digital health. ...
Posted by Michael Wonder on 21 Jan 2023
Sources of innovation in gene therapies - approaches to achieving affordable prices
21 January 2023 - Gene therapies are a fast growing area of innovation and potentially hold great promise for clinical care. ...
Posted by Michael Wonder on 21 Jan 2023
Novartis warns US plan to curb drug prices could hit key research
21 January 2023 - US Government plans to rein in drug prices could discourage work in some of Novartis' most ...
Posted by Michael Wonder on 17 Jan 2023
Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement
16 January 2023 - Pharmaceutical manufacturers in Canada often enter into product listing agreements, particularly with public payers, to facilitate their ...
Posted by Michael Wonder on 17 Jan 2023
Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe
16 January 2023 - Bayer has said it is shifting the focus of its pharmaceutical business to the US and ...
Posted by Michael Wonder on 12 Jan 2023
Intellia Therapeutics awarded Innovation Passport in the United Kingdom for NTLA-2002, an investigational genome editing treatment for hereditary angioedema
11 January 2023 - NTLA-2002 is a single dose genome editing therapeutic candidate designed to prevent angioedema attacks in people ...
Posted by Michael Wonder on 07 Dec 2022
An innovation surcharge to fund the repurposing of generic drugs
10 November 2022 - The use of generic drugs continues to increase, generating substantial savings for purchasers and improving affordable access ...
Posted by Michael Wonder on 29 Nov 2022
NICE’s new methods: putting innovation first, but at what cost?
28 November 2022 - Traditionally the gatekeeper to the NHS, NICE has increasingly reoriented its role towards facilitating access to innovative ...
Posted by Michael Wonder on 21 Nov 2022
New Quality Innovation Expert Group supports medicine innovation
21 November 2022 - The EMA has established a Quality Innovation Expert Group to support innovative approaches for the development, ...
Posted by Michael Wonder on 10 Nov 2022
Aleta Biotherapeutics receives Innovation Passport Designation for biologic CAR T-cell therapy engager ALETA-001
7 November 2022 - ALETA-001 was developed to address the urgent unmet need of patient relapse after CD19 targeted CAR ...
Posted by Michael Wonder on 08 Nov 2022
Blue Earth Therapeutics awarded UK MHRA innovation passport for investigational 177Lu-rhPSMA-10.1 for treatment of metastatic castrate-resistant prostate cancer
8 November 2022 - Lutetium LU 177 labeled radiohybrid prostate specific membrane antigen (Lu 177-rhPSMA-10.1) is an optimised therapeutic radiopharmaceutical. ...
Posted by Michael Wonder on 07 Sep 2022
FDA accepts Integral Molecular's letter of intent on membrane proteome array antibody specificity test into ISTAND drug development tools pilot program
7 September 2022 - Integral Molecular has been accepted into the US FDA's ISTAND pilot program. ...
Posted by Michael Wonder on 23 Aug 2022
The EU HTA regulation: a new frontier for access to innovative technologies
23 August 2022 - A new health technology regulation is due to be applied to help EU countries determine the effectiveness ...
Posted by Michael Wonder on 23 Aug 2022
AstraZeneca's Soriot warns new US drug price law will hurt innovation
23 August 2022 - AstraZeneca's Chief Executive Pascal Soriot warned on Tuesday new US legislation capping drug prices would reduce ...
Posted by Michael Wonder on 22 Aug 2022
Drug pricing reforms can hurt innovation. Here are 3 ways to prevent that.
22 August 2022 - Giving billions of dollars in government prize money to drug companies might sound like an idea from ...